Castiñeiras Fernández J, Cozar Olmo J M, Fernández-Pro A, Martín J A, Brenes Bermúdez F J, Naval Pulido E, Molero J M, Pérez Morales D
Hospital Universitario Virgen Macarena, Sevilla, España.
Actas Urol Esp. 2010 Jan;34(1):24-34. doi: 10.1016/s0210-4806(10)70007-3.
Benign prostatic hyperplasia (BPH) is a high prevalence condition in men over 50 years that requires continued assistance between primary care and urology. Therefore, consensus around common referral criteria was needed to guide and support both levels. Medical history, symptom assessment with International Prostate Symptom Score (IPSS) questionnaire, digital rectal examination and prostate-specific antigen (PSA) measurement are diagnostic tests available for general practitioners that allow setting a correct BPH diagnose. Patients with an IPSS<8 should be monitored by evaluating them annually. Treatment with alpha-blockers and an evaluation at the first and third month is recommended in patients with an IPSS 8-20 and if the prostate is small, if the prostate size is large treatment with alpha-blockers or 5alpha-reductase inhibitors and evaluation at the third and six month is recommended, and in patients with a large prostate and a PSA >1.5 ng/ ml combined treatment and evaluation at the first and sixth month is recommended. Some clear criteria for referral to urology are established in this document, which help in the management of these patients. Those patients with BPH who do not show any improvement at the third month of treatment with alpha-blockers, or the sixth month with 5alpha-reductase inhibitors, will be referred to urology. Patients will also be referred to urology if they have lower urinary tract symptoms, a pathological finding during rectal examination, IPSS>20, PSA>10 ng/ml or PSA>4 ng/ml and free PSA<20% or if they are <50 years with suspected BHP, or if they have any urological complication.
良性前列腺增生(BPH)是50岁以上男性中的一种高发性疾病,需要初级保健和泌尿外科之间持续的协作。因此,需要围绕常见的转诊标准达成共识,以指导和支持这两个层面的工作。病史、使用国际前列腺症状评分(IPSS)问卷进行症状评估、直肠指检和前列腺特异性抗原(PSA)检测是全科医生可用的诊断测试,有助于正确诊断BPH。IPSS<8的患者应每年进行评估以进行监测。对于IPSS为8-20且前列腺较小的患者,建议使用α受体阻滞剂治疗并在第一个月和第三个月进行评估;如果前列腺体积较大,建议使用α受体阻滞剂或5α还原酶抑制剂治疗并在第三个月和第六个月进行评估;对于前列腺体积较大且PSA>1.5 ng/ml的患者,建议联合治疗并在第一个月和第六个月进行评估。本文档制定了一些明确的泌尿外科转诊标准,有助于这些患者的管理。使用α受体阻滞剂治疗三个月或使用5α还原酶抑制剂治疗六个月后无任何改善的BPH患者,将被转诊至泌尿外科。如果患者有下尿路症状、直肠检查有病理发现、IPSS>20、PSA>10 ng/ml或PSA>4 ng/ml且游离PSA<20%,或者年龄<50岁且疑似BHP,或者有任何泌尿系统并发症,也将被转诊至泌尿外科。